Wendy Zadeh, MD
Neurology · Des Moines, IANPI 1194703074
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,684 of the $134,472 with a category attached, or 89.7%. AbbVie accounts for 81.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $37,439 and has fallen 75.4% since, to $9,227 in 2025. Among neurology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 500 payments — averaging $268.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$110K
- Biohaven Pharmaceuticals, Inc.$9K
- Biohaven Pharmaceutical Holding Company Ltd.$5K
- Axsome Therapeutics, Inc.$4K
- Livanova USA, Inc.$3K
- UCB, Inc.$1K
- plus $2K from 16 others
What the payments were for
- Consulting fees$3,0002%
- Speaking & faculty fees$120,68490%
- Travel & lodging$2,7892%
- Food & beverage$7,9066%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 223 | $109,624 |
| Biohaven Pharmaceuticals, Inc. | 20 | $8,818 |
| Biohaven Pharmaceutical Holding Company Ltd. | 18 | $5,440 |
| Axsome Therapeutics, Inc. | 9 | $4,085 |
| Livanova USA, Inc. | 79 | $2,979 |
| UCB, Inc. | 34 | $1,115 |
| SK Life Science, Inc. | 32 | $706 |
| Lilly USA, LLC | 29 | $537 |
| Teva Pharmaceuticals USA, Inc. | 17 | $355 |
| Lundbeck LLC | 6 | $192 |
| Pfizer | 10 | $155 |
| Jazz Pharmaceuticals Inc. | 5 | $131 |
| Amgen | 4 | $69 |
| Neurelis, Inc. | 2 | $64 |
| Novartis | 3 | $60 |
| Zogenix Inc. | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 3 | $25 |
| Adamas Pharmaceuticals, Inc. | 1 | $22 |
| GRT US Holding, Inc. | 1 | $19 |
| Greenwich Biosciences, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$56,860
- BOTOX$41,188
- QULIPTA$25,902
- NURTEC ODT$13,875
- Symbravo$3,970
- VNS Therapy$1,644
- Briviact$750
- XCOPRI$125
How this compares
$134,472 in reported general payments places this provider in the 95th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 11 | $222,915 |
| Nurtec OdtRimegepant Sulfate | 113 | $155,570 |
| AustedoDeutetrabenazine | 20 | $125,154 |
| UbrelvyUbrogepant | 70 | $103,155 |
| KeppraLevetiracetam | 51 | $78,406 |
| QuliptaAtogepant | 60 | $74,236 |
| BriviactBrivaracetam | 50 | $70,988 |
| EpidiolexCannabidiol (Cbd) | 37 | $70,394 |
| Keppra XrLevetiracetam | 24 | $44,431 |
| Emgality PenGalcanezumab-Gnlm | 58 | $43,968 |
| Lacosamide | 255 | $43,416 |
| ValtocoDiazepam | 43 | $32,248 |
| VimpatLacosamide | 26 | $30,121 |
| FelbatolFelbamate | 12 | $27,332 |
| XcopriCenobamate | 18 | $22,447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $109,624 | $177,390130 claims |
| PfizerNurtec Odt, Dilantin | $155 | $164,973153 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $355 | $125,15420 claims |
| UCB, Inc.Briviact, Vimpat, Neupro | $1,115 | $111,06088 claims |
| Neurelis, Inc.Valtoco | $64 | $32,24843 claims |
| SK Life Science, Inc.Xcopri | $706 | $22,44718 claims |
| Lundbeck LLCOnfi | $192 | $21,53512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 132 neurology providers in Iowa.
Other neurology in Des Moines
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Paul BabikianDes Moines$107K
- Mark PuricelliDes Moines$45K
- Keith KohoutDes Moines$36K
- Erik ArnesonDes Moines$10K
- John WrightDes Moines$9K
- Lynn StruckDes Moines$6K
- Irving WolfeDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.